Fresh analysis suggests that individuals who come off new weight-loss injections like semaglutide or tirzepatide may regain reduced body mass far faster than those who stop conventional lifestyle plans.
Findings released in a major medical journal shows that while overweight people can lose substantial amounts of their body weight while on the medication, the weight returns at an estimated rate of 0.8 kg per month after stopping.
"Users buying these treatments must be informed of the potential of quick rebound weight gain when the treatment ends," cautioned lead investigator Dr. Susan Jebb.
This pace of regain means a return to pre-treatment weight in about a year and a half.
Analyzing Therapies
The study, which examined 37 of studies involving over 9,000 of participants, compared the effects of GLP-1 agonists with older methods.
Researchers emphasize that individuals who shed pounds through diet and exercise generally experience a more gradual creep back—around 100 grams monthly—once they finish.
Explaining the Fast Regain
Doctors suggest the way of the jabs explains the heightened rebound.
These medications imitate a natural hormone called GLP-1, which helps regulate feelings of fullness.
"Artificially providing GLP-1 levels several times higher than normal might result in the body to generate a reduced amount of its endogenous hormone, and could diminish sensitivity to its effects," explained Dr. Adam Collins, a dietetics researcher.
"Stopping of this hormone supplement means appetite is uncontrolled, making excessive eating much more probable."
A Lifelong Issue?
The NHS advise the injections for individuals with weight-linked medical conditions, alongside prescribed lifestyle changes.
Many experts contend that, given the likelihood of weight regain, the treatment is often ongoing.
This opinion is echoed by pharmaceutical companies, who state that the results "highlight the persistent nature of excess weight," comparing it to managing conditions like diabetes.
User Accounts
People who have discontinued the medication report a sudden resurgence of appetite.
"It felt as if a switch that goes on and I was suddenly extremely hungry," said an individual.
This difficulty is compounded if patients have not developed sustainable lifestyle or habit changes during therapy.
Growing Use
Recent estimates indicate that millions of people in the UK have used weight-loss jabs in the last 12 months, with desire being substantial.
- Adoption is greater among females compared to men.
- The 40s and 50s age group shows the highest usage rates.
- Many access the drugs through private healthcare rather than public health services.
Finally, researchers caution that while GLP-1 drugs are potent agents for weight loss, they are not a magic fix and maintained weight loss likely depends on integrated lifestyle management.
